Invoking 35 U.S.C. § 202 and 28 U.S.C. § 1498 to allow generic competitors to enter the market prior to drug patent expiry is a direct attack on patent rights. HHS must reject it.

Conservatives urge PTO to disavow and end appealed PTAB cases where Intel, Open Sky and PQA repeatedly challenge VLSI's patents, and Biden's PTO egregiously applying the repudiated "compelling merits" standard.

Acting Director Stewart seeks to ensure PTO's fair treatment and giving weight to “settled expectations” of inventors and patent owners. She's restoring “quiet title” through reliable, secure patent rights.

MFN would embed foreign governments' socialist price controls into American law. That will punish U.S. innovators, investors and patients. Access barriers, hundreds fewer new drugs, China Rx R&D advantaged.

CPR urges Senators to oppose MFN because importing foreign price controls into America’s health system wouldn't help Americans afford their medicines or end foreign freeloading.

CMS proposes imposing price controls on new, separately patented medicines the moment they reach the market simply because they are related to older drugs.

Thirty center-right groups voiced support for bipartisan, bicameral PREVAIL, PERA, and RESTORE Patent Rights Acts.

CPR joined more than 30 allied groups advocating for the U.S. Senate to retain health savings account provisions in the budget reconciliation bill.

CPR and allies from CASM urged Congress not to include "most favored nation" price controls in the budget reconciliation bill.

Related CPR's strong opposition to the Energy & Commerce Committee's including MFN price controls in Medicaid or other health reforms in budget reconciliation.

Conveyed strong opposition to Congress limiting the ability of businesses to deduct state and local taxes paid -- a longstanding “ordinary and necessary expense” -- in budget reconciliation.

Support for H.R. 2230, the Independent Programmers Tax Incentive Act, which would foster production and carriage of values-based programming content.

PREVAIL reforms the Patent Trial and Appeal Board, which has been subject to abuse by patent infringers, Big Tech, Chinese national champions, and even hedge funds.

The Patent Eligibility Restoration Act the would restore the breadth and certainty of what constitutes patent-eligible subject matter. CPR strongly supports PERA.

Congressional Review Act motion to cancel EPA's waiver from Clean Air Act, which allows California's strict emissions rules to force an electric vehicle mandate on all states.

Told Sec. Lutnick that PTO's Acting Director Coke Stewart is showing strong leadership to restore fairness, clarity, and reliability to U.S. patents and for patent owners.

Warned about four bills that threaten to undermine vital foundational principles. Exposed misconceptions about the patent system and the innovation process. Urged not to weaken the framework behind centuries of American technological progress.

Advised Commerce Secretary Lutnick of concerns regarding adverse policy options under consideration that would actually benefit China and harm American innovation and technological leadership.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Responded to PTO explaining why the introduction of genetic resource disclosure requirements would cause significant legal uncertainties in the patent system.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Informing a House Energy and Commerce subcommittee of an inaccurate picture of drug patents a witness painted in its PBM hearing, CPR set the record straight.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Conservatives Against Socialized Medicine told Senate and House leaders it favors eliminating the "pill penalty" in the budget reconciliation bill.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

The RESTORE Patent Rights Act would return access to injunctions to patent owners who've proven patent validity and infringement, as it was before the courts wrongfully denied it.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

About 200 organizations wrote Congress expressing their support for eliminating the estate tax.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

CPR tells Congress the clear message in Special 301 reports must be the United States defends its citizens' IP rights abroad.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Conservatives Against Socialized Medicine urges Trump to stop Biden's IRA price controls from triggering the next stage of CMS dictating drug prices in Medicare.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 As Congress begins work on tax legislation, this letter points out the benefits of the 2017 corporate tax rate of 21% for American competitiveness and average Americans.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 Conservatives asked House leaders to bring up PBM reforms helping patient access to medicines and lower out-of-pocket costs.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 Conservative leaders offer Trump team ways to win innovation leadership by outcompeting China, the EU and others.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Blurb:  

The Medication Affordability and Patent Integrity Act is well-intentioned, but would hinder innovation and  expose valuable U.S. trade secrets.

 Conservative leaders voice support to Senators for patent bills. PREVAIL removes bias at PTAB, and PERA cancels judicial exceptions to matter that’s patent-eligible. 

 We urge Congress to protect U.S. national security by shoring up the policy underpinnings that will protect our country’s innovation leadership in key technologies. 

 CPR supports PERA because it shifts from the unworkable ‘Alice-Mayo Framework’ to clear, broad standards for determining what subject matter is patent-eligible. 

 This bipartisan, bicameral bill restores access to injunctions in cases where patents are proven infringed. The RESTORE Act corrects a judicially created error of injustice. 

The ITC’s evidence-based process protects U.S. innovators. Congress shouldn’t reward IP infringers and Chinese manufacturers by weakening it.

CPR agrees with bipartisan, former top PTO officials that this must be immediately withdrawn. (If there’s room, include: Its far-reaching lengths are contrary to statute.)

Marcum's new study of patent litigation shows that civil litigation now holds less promise of delivering justice to inventors and patent owners.

H.R. 3535 adds hurdles to the U.S. International Trade Commission’s ability to keep IP-infringing products out, enabling infringers to keep supply chains in China.

The Restoring America’s Leadership in Innovation Act would strengthen private intellectual property rights. RALIA would reverse the antipatent onslaught of recent years.

The Sunset Act reins in the Administrative State's rules, regulations, and guidance. They would no longer remain in force in perpetuity.

These excerpt public comments that oppose the Biden draft guidance for Bayh-Dole march-in to forcibly relicense patents if an agency disagrees with the product price.

H.R. 6758 enables property owners to hold the federal government accountable for takings. Its more efficient, uniform process secures Fifth Amendment rights.